Abstract:<p>Selective inhibition of cyclin-dependent kinase 8 (CDK8) has been recently regarded as a potential approach for cancer therapy. A series of novel CDK8 inhibitors with the pyridine core was identified via scaffold hopping from the known CDK8 inhibitor A-7. The new inhibitors were designed to improve the ligand efficiency so as to enhance drug-likeness. Most of the compounds showed significant inhibition against CDK8/cyclin C, and the most active compounds (5d, 5e and 7') displayed IC<sub>50</sub> values of 2.4 nM, 5.0 nM and 7.7 nM, respectively. Preliminary kinase profiling of selected compounds against a panel of kinases from different families indicated that this compound class might selectively inhibit CDK8 as well as its paralog CDK19. Some compounds exhibited cellular activity in both MTT and SRB assays against a variety of tumor cells, including HCT-116, A549, MDA-MB-231, KB, KB-VIN and MCF-7. Further flow cytometry analysis revealed a dose-dependent G2/M phase arrest in MDA-MB-231 cells treated with compounds 6'a, 6'b, 6'j and 6'k. In addition, compound 6'k demonstrated moderate antitumor efficacy in HCT-116 mouse models, although unfavorable pharmacokinetic profiles were suggested by preliminary study in mice. The results provided a new structural prototype for the search of selective CDK8 inhibitors as antitumor agents.</p>

Nitrogen-containing Flavonoids As CDK1/Cyclin B Inhibitors: Design, Synthesis, and Biological Evaluation

Nitrogen-containing flavonoid analogues as CDK1/cyclin B inhibitors: synthesis, SAR analysis, and biological activity.

Design, Synthesis and Preliminary Biological Evaluation of Purine‐2,6‐diamine Derivatives As Cyclin‐dependent Kinase (CDK) Inhibitors

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Design, Synthesis and Biological Evaluation of Pteridine-7(8H)-one Derivatives As Potent and Selective CDK4/6 Inhibitors

Design, Synthesis, Antitumour Evaluation, and In Silico Studies of Pyrazolo-[1,5-c]quinazolinone Derivatives Targeting Potential Cyclin-Dependent Kinases

Design, Synthesis, and Biological Evaluation of Novel Γ-Carboline Ketones As Anticancer Agents

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

Selective and Novel Cyclin-Dependent Kinases 4 Inhibitor: Synthesis and Biological Evaluation

Design, Synthesis and Biological Evaluation of N-alkyl or Aryl Substituted Isoindigo Derivatives As Potential Dual Cyclin-Dependent Kinase 2 (cdk2)/glycogen Synthase Kinase 3β (Gsk-3Β) Phosphorylation Inhibitors.

Design, Synthesis and Biological Evaluation of Pyrimidine Derivatives As Novel CDK2 Inhibitors That Induce Apoptosis and Cell Cycle Arrest in Breast Cancer Cells.

Design, Synthesis, and Biological Evaluation of 4-Phenoxyquinoline Derivatives As Potent C-Met Kinase Inhibitor

Design, Synthesis, and Biological Evaluation of Novel 4‐phenoxypyridine Derivatives As Potential Antitumor Agents

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

The in Vitro Anti-Cancer Effects of Wogonin in Human Cancer Cells

Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors

Synthesis And In Vitro Cytotoxic Evaluation Of Novel -(3,4,5-Trimethoxyphenyl)Pyridin-2()-One Derivatives

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxyquinoline Derivatives Containing 3-Oxo-3,4-dihydroquinoxaline Moiety As C-Met Kinase Inhibitors

Design, Synthesis and Biological Evaluation of Chromone Derivatives As Novel Protein Kinase CK2 Inhibitors